SEARCH

SEARCH BY CITATION

References

  • 1
    Zitvogel, L., Tesniere, A. and Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006. 6: 715727.
  • 2
    Vignali, D. A., Collison, L. W. and Workman, C. J., How regulatory T cells work. Nat. Rev. Immunol. 2008. 8: 523532.
  • 3
    Piconese, S., Valzasina, B. and Colombo, M. P., OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 2008. 205: 825839.
  • 4
    Vu, M. D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., Killeen, N. et al., OX40 costimulation turns off Foxp3+ Tregs. Blood 2007. 110: 25012510.
  • 5
    So, T. and Croft, M., Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 2007. 179: 14271430.
  • 6
    Ito, T., Wang, Y. H., Duramad, O., Hanabuchi, S., Perng, O. A., Gilliet, M., Qin, F. X. et al., OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. USA 2006. 103: 1313813143.
  • 7
    Ishii, N., Takahashi, T., Soroosh, P. and Sugamura, K., OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv. Immunol. 2010. 105: 6398.
  • 8
    Croft, M., Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 2010. 28: 5778.
  • 9
    Xiao, X., Kroemer, A., Gao, W., Ishii, N., Demirci, G. and Li, X. C., OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by expanding memory T cells in vivo. J. Immunol. 2008. 181: 31933201.
  • 10
    Song, J., So, T. and Croft, M., Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J. Immunol. 2008. 180: 72407248.
  • 11
    Rogers, P. R., Song, J., Gramaglia, I., Killeen, N. and Croft, M., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001. 15: 445455.
  • 12
    Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J. et al., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 21602169.
  • 13
    Dercamp, C., Chemin, K., Caux, C., Trinchieri, G. and Vicari, A. P., Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res. 2005. 65: 84798486.
  • 14
    Saraiva, M. and O'Garra, A., The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010. 10: 170181.
  • 15
    Uhlig, H. H., Coombes, J., Mottet, C., Izcue, A., Thompson, C., Fanger, A., Tannapfel, A. et al., Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J. Immunol. 2006. 177: 58525860.
  • 16
    Sallusto, F. and Lanzavecchia, A., Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur. J. Immunol. 2009. 39: 20762082.
  • 17
    Martin-Fontecha, A., Baumjohann, D., Guarda, G., Reboldi, A., Hons, M., Lanzavecchia, A. and Sallusto, F., CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming. J. Exp. Med. 2008. 205: 25612574.
  • 18
    Mackey, M. F., Gunn, J. R., Maliszewsky, C., Kikutani, H., Noelle, R. J. and Barth, R. J., Jr., Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 1998. 161: 20942098.
  • 19
    Murugaiyan, G., Agrawal, R., Mishra, G. C., Mitra, D. and Saha, B., Differential CD40/CD40L expression results in counteracting antitumor immune responses. J. Immunol. 2007. 178: 20472055.
  • 20
    Pardee, A. D., McCurry, D., Alber, S., Hu, P., Epstein, A. L. and Storkus, W. J., A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 2010. 70: 90419052.
  • 21
    Gough, M. J., Ruby, C. E., Redmond, W. L., Dhungel, B., Brown, A. and Weinberg, A. D., OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 2008. 68: 52065215.
  • 22
    Madan, R., Demircik, F., Surianarayanan, S., Allen, J. L., Divanovic, S., Trompette, A., Yogev, N. et al., Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J. Immunol. 2009. 183: 23122320.
  • 23
    Ziegler-Heitbrock, L., Lotzerich, M., Schaefer, A., Werner, T., Frankenberger, M. and Benkhart, E., IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 2003. 171: 285290.
  • 24
    Warfel, J. M. and D'Agnillo, F., Anthrax lethal toxin enhances TNF-induced endothelial VCAM-1 expression via an IFN regulatory factor-1-dependent mechanism. J. Immunol. 2008. 180: 75167524.
  • 25
    Stirnweiss, A., Ksienzyk, A., Klages, K., Rand, U., Grashoff, M., Hauser, H. and Kroger, A., IFN regulatory factor-1 bypasses IFN-mediated antiviral effects through viperin gene induction. J. Immunol. 2010. 184: 51795185.
  • 26
    Elgueta, R., Benson, M. J., de Vries, V. C., Wasiuk, A., Guo, Y. and Noelle, R. J., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009. 229: 152172.
  • 27
    Chiodoni, C., Paglia, P., Stoppacciaro, A., Rodolfo, M., Parenza, M. and Colombo, M. P., Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 1999. 190: 125133.
  • 28
    Hanig, J. and Lutz, M. B., Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J. Immunol. 2008. 180: 14051413.
  • 29
    Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K. and Anderson, A. C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010. 207: 21872194.
  • 30
    Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G. and Rudensky, A. Y., Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005. 22: 329341.
  • 31
    Maynard, C. L., Harrington, L. E., Janowski, K. M., Oliver, J. R., Zindl, C. L., Rudensky, A. Y. and Weaver, C. T., Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol. 2007. 8: 931941.
  • 32
    Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P. et al., Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008. 28: 546558.
  • 33
    Gounaris, E., Blatner, N. R., Dennis, K., Magnusson, F., Gurish, M. F., Strom, T. B., Beckhove, P. et al., T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 2009. 69: 54905497.
  • 34
    Mosser, D. M. and Zhang, X., Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 2008. 226: 205218.
  • 35
    Vicari, A. P., Chiodoni, C., Vaure, C., Ait-Yahia, S., Dercamp, C., Matsos, F., Reynard, O. et al., Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 2002. 196: 541549.
  • 36
    Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G. and Colombo, M. P., Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005. 65: 34373446.
  • 37
    Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T. and Whiteside, T. L., A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007. 13: 43454354.
  • 38
    Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942949.
  • 39
    Klages, K., Mayer, C. T., Lahl, K., Loddenkemper, C., Teng, M. W., Ngiow, S. F., Smyth, M. J. et al., Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010. 70: 77887799.
  • 40
    Teng, M. W., Ngiow, S. F., von Scheidt, B., McLaughlin, N., Sparwasser, T. and Smyth, M. J., Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010. 70: 78007809.
  • 41
    Vieira, P. L., Christensen, J. R., Minaee, S., O'Neill, E. J., Barrat, F. J., Boonstra, A., Barthlott, T. et al., IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004. 172: 59865993.
  • 42
    Ito, T., Wang, Y. H., Duramad, O., Hori, T., Delespesse, G. J., Watanabe, N., Qin, F. X. et al., TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp. Med. 2005. 202: 12131223.
  • 43
    Humphreys, I. R., de Trez, C., Kinkade, A., Benedict, C. A., Croft, M. and Ware, C. F., Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J. Exp. Med. 2007. 204: 12171225.
  • 44
    Kano, S., Sato, K., Morishita, Y., Vollstedt, S., Kim, S., Bishop, K., Honda, K. et al., The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat. Immunol. 2008. 9: 3441.
  • 45
    Feuerer, M., Hill, J. A., Kretschmer, K., von Boehmer, H., Mathis, D. and Benoist, C., Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc. Natl. Acad. Sci. USA 2010. 107: 59195924.
  • 46
    Lal, G., Yin, N., Xu, J., Lin, M., Schroppel, S., Ding, Y., Marie, I. et al., Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of foxp3 expression and treg function. Am. J. Transplant. 2011. 11: 203214.
  • 47
    Barnes, M. J. and Powrie, F., Hybrid Treg cells: steel frames and plastic exteriors. Nat. Immunol. 2009. 10: 563564.
  • 48
    Koch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B. and Campbell, D. J., The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 2009. 10: 595602.
  • 49
    Lu, L. F., Boldin, M. P., Chaudhry, A., Lin, L. L., Taganov, K. D., Hanada, T., Yoshimura, A. et al., Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010. 142: 914929.
  • 50
    Feuerer, M., Hill, J. A., Mathis, D. and Benoist, C., Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 2009. 10: 689695.
  • 51
    Zhou, X., Bailey-Bucktrout, S., Jeker, L. T. and Bluestone, J. A., Plasticity of CD4(+) FoxP3(+) T cells. Curr. Opin. Immunol. 2009. 21: 281285.
  • 52
    Hori, S., Developmental plasticity of Foxp3+ regulatory T cells. Curr. Opin. Immunol. 2010. 22: 575582.
  • 53
    Sharma, M. D., Hou, D. Y., Baban, B., Koni, P. A., He, Y., Chandler, P. R., Blazar, B. R. et al., Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010. 33: 942954.
  • 54
    Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D. and Colombo, M. P., Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005. 105: 28452851.
  • 55
    Ruby, C. E., Yates, M. A., Hirschhorn-Cymerman, D., Chlebeck, P., Wolchok, J. D., Houghton, A. N., Offner, H. et al., Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J. Immunol. 2009. 183: 48534857.
  • 56
    Piconese, S., Pittoni, P., Burocchi, A., Gorzanelli, A., Care, A., Tripodo, C. and Colombo, M. P., A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur. J. Immunol. 2010. 40: 29022913.
  • 57
    MacMicking, J. D., IFN-inducible GTPases and immunity to intracellular pathogens. Trends Immunol. 2004. 25: 601609.
  • 58
    Griseri, T., Asquith, M., Thompson, C. and Powrie, F., OX40 is required for regulatory T cell-mediated control of colitis. J. Exp. Med. 2010. 207: 699709.
  • 59
    al-Shamkhani, A., Birkeland, M. L., Puklavec, M., Brown, M. H., James, W. and Barclay, A. N., OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 1996. 26: 16951699.
  • 60
    Lindgren, H., Axcrona, K. and Leanderson, T., Regulation of transcriptional activity of the murine CD40 ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2. J. Immunol. 2001. 166: 45784585.
  • 61
    So, T., Soroosh, P., Eun, S. Y., Altman, A. and Croft, M., Antigen-independent signalosome of CARMA1, PKCtheta, and TNF receptor-associated factor 2 (TRAF2) determines NF-kappaB signaling in T cells. Proc. Natl. Acad. Sci. USA 2011. 108: 29032908.
  • 62
    Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I., Schumacher, T. N., Melief, C. J., Offringa, R. et al., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999. 5: 774779.
  • 63
    French, R. R., Chan, H. T., Tutt, A. L. and Glennie, M. J., CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999. 5: 548553.
  • 64
    Sotomayor, E. M., Borrello, I., Tubb, E., Rattis, F. M., Bien, H., Lu, Z., Fein, S. et al., Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 1999. 5: 780787.
  • 65
    Gri, G., Gallo, E., Di Carlo, E., Musiani, P. and Colombo, M. P., OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J. Immunol. 2003. 170: 99106.